Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company committed to revolutionizing the field of oncology through the development and delivery of innovative, targeted cancer therapies. This Los Angeles-based company was founded in 2016 and, since its inception, has been diligent in its mission to address the unmet needs in the cancer treatment realm.
A crucial aspect of Immix Biopharma's work lies in its dedication to create therapies that not only target cancer cells but also modulate the tumor immune microenvironment. This dual approach results in a comprehensive treatment that works against cancer on multiple fronts, thereby ensuring minimal chances of relapse. As a result, the company's research and work go beyond just treatment. They have the potential to increase the quality of life and the prognosis for patients worldwide.
Immix’s proprietary technology, Imx-110, is setting new standards in the industry. Imx-110 is a first-in-class combination therapy designed to counteract a multitude of solid tumors. Unlike traditional oncology treatments that focus on eliminating the visible symptoms, Imx-110 targets the microenvironment and the tumor, making it a groundbreaking approach to treating cancer.
As a specialized general benefit corporation, Immix Biopharma, Inc. is known for its socially responsible and environmentally sustainable practices. The company has demonstrated its commitment to reducing the environmental impact of manufacturing drugs by implementing cleaner production processes. Furthermore, they have exhibited their dedication to ethical practices by prioritizing patient outcomes and advocating for affordable access to life-saving treatments.
Immix Biopharma's focus on comprehensive research, innovation, and ethical practices has garnered significant recognition within the industry. The company has not only established productive partnerships with renowned institutions like Johns Hopkins University, but also successfully raised substantial funding from investors interested in their unique approach to oncology.
The company is led by an experienced team of professionals from various backgrounds in science, healthcare, and business. They share a collective vision for pursuing groundbreaking therapies and aim to enhance the experiences of patients with cancer through their work. Despite being relatively new to the field, the company is establishing promising momentum and is on track to becoming a formidable contender in the world of biopharmaceuticals.
In conclusion, Immix Biopharma, Inc. is not merely a biopharmaceutical company. It is a beacon of hope in the intensive fight against cancer. The company's work goes beyond the measures of profit or success; it lies in changing lives and redefining the future of cancer treatments.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Mizuho has increased its price target for Immix Biopharma (NASDAQ:IMMX) to $26 from $15, maintaining an Outperform rating, due to the potential for NXC-201 in first-line AL amyloidosis, which could generate over $2 billion in peak revenue. The firm projects a Phase 3 study for this indication in early 2027 and holds high conviction in upcoming Phase 2 data for NXC-201 in relapsed/refractory AL amyloidosis. This update comes amidst other analyst upgrades and the recent arrest of an Immix Biopharma executive.
Tocqueville Asset Management L.P. has acquired a new position in Immix Biopharma, Inc. (NASDAQ:IMMX), purchasing 88,550 shares valued at approximately $913,000, giving them a 0.16% stake. Other institutional investors have also increased their holdings. Analysts currently rate Immix Biopharma as a "Moderate Buy" with a consensus price target of $21.29, despite the company recently reporting a quarterly loss worse than estimates.
Blue Owl Capital Holdings LP has initiated a new investment in Immix Biopharma, Inc. (NASDAQ:IMMX), acquiring 437,552 shares valued at approximately $4.51 million. This makes Immix Biopharma the 24th largest position in Blue Owl's portfolio, representing about 0.7% of its total holdings. The article also notes recent adjustments by other institutional investors and provides an overview of analyst ratings and the company's financial performance.
Immix Biopharma (NASDAQ:IMMX) recently hit a new 52-week high of $12.76, closing at $11.81. Analysts maintain a "Moderate Buy" consensus with a target price of $21.29, despite the company reporting a quarterly loss of $0.18 per share, slightly missing estimates. Institutional investors hold 11.26% of the company, which is focused on developing immuno-oncology therapies targeting myeloid checkpoints.
Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and a $21.29 price target, and institutional ownership stands at 11.26%, including a new significant position from BlackRock Inc.